376 related articles for article (PubMed ID: 30245442)
21. Clinical characteristics and management experience of unexpected uterine sarcoma after myomectomy.
Zhang J; Zhang J; Dai Y; Zhu L; Lang J; Leng J
Int J Gynaecol Obstet; 2015 Aug; 130(2):195-9. PubMed ID: 26117552
[TBL] [Abstract][Full Text] [Related]
22. Risk of unexpected uterine leiomyosarcoma during laparoscopic procedures: Experience from a single tertiary institute in Italy.
Surace A; Baù MG; Privitera S; Botta G; Danese S; Plazzotta C; Mitidieri M; Picardo E
Int J Gynaecol Obstet; 2022 Feb; 156(2):236-239. PubMed ID: 33834486
[TBL] [Abstract][Full Text] [Related]
23. Occult Leiomyosarcomas in a Canadian Province: A Retrospective Cohort Study.
Wu CQ; Woo LY; Giede KC; Thiel J; Karreman E; Rattray DD
J Obstet Gynaecol Can; 2019 Jan; 41(1):46-51. PubMed ID: 30341020
[TBL] [Abstract][Full Text] [Related]
24. Nonmalignant Sequelae of Unconfined Morcellation at Laparoscopic Hysterectomy or Myomectomy.
Tulandi T; Leung A; Jan N
J Minim Invasive Gynecol; 2016; 23(3):331-7. PubMed ID: 26802909
[TBL] [Abstract][Full Text] [Related]
25. Power morcellation for women undergoing laparoscopic supracervical hysterectomy - safety of procedure and clinical experience from 426 cases.
Rechberger T; Miotła P; Futyma K; Ziętek A; Filipczak A; Rechberger E; Szumiło J; Adamiak-Godlewska A
Ginekol Pol; 2016; 87(8):546-51. PubMed ID: 27629127
[TBL] [Abstract][Full Text] [Related]
26. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
Raspagliesi F; Maltese G; Bogani G; Fucà G; Lepori S; De Iaco P; Perrone M; Scambia G; Cormio G; Bogliolo S; Bergamini A; Bifulco G; Casali PG; Lorusso D
Gynecol Oncol; 2017 Jan; 144(1):90-95. PubMed ID: 27817933
[TBL] [Abstract][Full Text] [Related]
27. Long-term sequelae of unconfined morcellation during laparoscopic gynecological surgery.
Cohen A; Tulandi T
Maturitas; 2017 Mar; 97():1-5. PubMed ID: 28159054
[TBL] [Abstract][Full Text] [Related]
28. Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients.
Cao H; Li L; Yang B; Luo G; Lou J; Xi M
Cancer Manag Res; 2019; 11():7007-7014. PubMed ID: 31440089
[TBL] [Abstract][Full Text] [Related]
29. The Morcellation Debate: The History and the Science.
Adelman MR
Clin Obstet Gynecol; 2015 Dec; 58(4):710-7. PubMed ID: 26512438
[TBL] [Abstract][Full Text] [Related]
30. A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma.
Wais M; Tepperman E; Bernardini MQ; Gien LT; Jimenez W; Murji A
J Obstet Gynaecol Can; 2017 Aug; 39(8):652-658. PubMed ID: 28729098
[TBL] [Abstract][Full Text] [Related]
31. Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids.
Cui RR; Wright JD
Clin Obstet Gynecol; 2016 Mar; 59(1):103-18. PubMed ID: 26645385
[TBL] [Abstract][Full Text] [Related]
32. Minilaparotomy Versus Laparoscopic Myomectomy After Cessation of Power Morcellation: Rate of Wound Complications.
Dubin AK; Wei J; Sullivan S; Udaltsova N; Zaritsky E; Yamamoto MP
J Minim Invasive Gynecol; 2017; 24(6):946-953. PubMed ID: 28552622
[TBL] [Abstract][Full Text] [Related]
33. ACOG Committee Opinion No. 770 Summary: Uterine Morcellation for Presumed Leiomyomas.
Obstet Gynecol; 2019 Mar; 133(3):604-605. PubMed ID: 30801469
[TBL] [Abstract][Full Text] [Related]
34. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease.
Von Bargen EC; Grimes CL; Mishra K; Wang R; Haviland MJ; Hacker MR; Carnevale JA; Estes AJ; Elkadry EA
Int J Gynaecol Obstet; 2017 May; 137(2):123-128. PubMed ID: 28170091
[TBL] [Abstract][Full Text] [Related]
36. Racial Disparities in Response to a US Food and Drug Administration Safety Communication Regarding the Use of Power Morcellation for the Treatment of Uterine Leiomyoma.
Matsushita T; Sekizawa A; Jacobs LK
J Minim Invasive Gynecol; 2020 Jan; 27(1):178-185.e1. PubMed ID: 30936031
[TBL] [Abstract][Full Text] [Related]
37. Risk of morcellation of uterine leiomyosarcomas in laparoscopic supracervical hysterectomy and laparoscopic myomectomy, a retrospective trial including 4791 women.
Parker W; Pritts E; Olive D
J Minim Invasive Gynecol; 2015; 22(4):696-7. PubMed ID: 25623370
[No Abstract] [Full Text] [Related]
38. Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.
Glaser LM; Friedman J; Tsai S; Chaudhari A; Milad M
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():99-112. PubMed ID: 29078975
[TBL] [Abstract][Full Text] [Related]
39. Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A; Farghaly SA
Minerva Ginecol; 2018 Feb; 70(1):84-88. PubMed ID: 28975775
[TBL] [Abstract][Full Text] [Related]
40. Electric morcellation-related reoperations after laparoscopic myomectomy and nonmyomectomy procedures.
Pereira N; Buchanan TR; Wishall KM; Kim SH; Grias I; Richard SD; Della Badia CR
J Minim Invasive Gynecol; 2015 Feb; 22(2):163-76. PubMed ID: 25218993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
